Clinical trials: Glomerulonephritis
Primary IgA Nephropathy
Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)
This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study Nef-301 and continue to be treated with a…
- Trial name
- Nefigard-OLE (NCT04541043)
- Testing
- Nefecon 16mg daily
- Where
- 18 sites in United States, Argentina and 16 more
- Volunteers
- 119 people
- Sponsor
- Calliditas Therapeutics AB
Primary IgA Nephropathy
Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
The overall aim of the study is to evaluate the efficacy, safety, and tolerability of Nefecon 16 mg per day in the treatment of patients with primary IgAN (Immunoglobulin A nephropathy) at risk of progressing to end-stage renal…
- Trial name
- Nefigard (NCT03643965)
- Testing
- Nefecon
- Where
- 142 sites in United States, Argentina and 17 more
- Volunteers
- 365 people
- Sponsor
- Calliditas Therapeutics AB
Idiopathic Membranous Nephropathy
Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy
This was a randomized, open-label, two arm, parallel group, proof-of-concept, nonconfirmatory study evaluating the efficacy and safety of LNP023 compared with rituximab in subjects with Idiopathic (primary) membranous nephropathy…
- Trial name
- NCT04154787
- Testing
- LNP023, Rituximab
- Where
- 18 sites in Argentina, China and 7 more
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy (IgAN), Berger Disease
A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite standard of care, which includes treatment…
- Conditions
- IgA Nephropathy (IgAN), Berger Disease, Glomerulonephritis, IgA
- Trial name
- NCT03841448
- Testing
- Cemdisiran
- Where
- 17 sites in Canada, France and 7 more
- Volunteers
- 31 people
- Sponsor
- Alnylam Pharmaceuticals
Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy
Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.
- Conditions
- Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, Membranous Nephropathy
- Trial name
- RENEW (NCT05162066)
- Testing
- BCX9930
- Where
- 11 sites in France, Italy and 2 more
- Volunteers
- 2 people
- Sponsor
- BioCryst Pharmaceuticals
Glomerulonephritis
Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted
The study is an open-label, two cohort non-randomized study evaluating the efficacy, safety, and pharmacokinetics of LNP023 in patients with C3G (Cohort A) and patients who have undergone kidney transplant and have C3G recurrence…
- Trial name
- NCT03832114
- Testing
- LNP023
- Where
- 9 sites in United States, France and 4 more
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
C3 Glomerulonephritis, C3 Glomerulopathy
A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471
The primary purpose of this study was to evaluate the efficacy of 12 months of oral ACH-0144471 (also known as danicopan and ALXN2040) in participants with C3G or IC-MPGN based on histologic scoring and proteinuria.
- Conditions
- C3 Glomerulonephritis, C3 Glomerulopathy, Immune Complex Membranoproliferative Glomerulonephritis, IC-MPGN
- Trial name
- NCT03459443
- Testing
- Danicopan
- Where
- 13 sites in United States, Australia and 3 more
- Volunteers
- 22 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
IgA Nephropathy
Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
Efficacy and safety of LNP023 in IgAN patients
- Trial name
- NCT03373461
- Testing
- LNP023
- Where
- 56 sites in Argentina, Australia and 23 more
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
C3 Glomerulopathy, C3 Glomerulonephritis
A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
The primary purpose of this proof-of-concept clinical study was to evaluate the efficacy and safety of the study drug, ACH-0144471 (also known as danicopan and ALXN2040), in participants with C3G who also had significant…
- Conditions
- C3 Glomerulopathy, C3 Glomerulonephritis, Dense Deposit Disease
- Trial name
- NCT03369236
- Testing
- Danicopan
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Membranoproliferative Glomerulonephritis
Daratumumab in Treatment of PGNMID and C3 GN
This study is being done to see if daratumumab is safe and effective in the treatment of proliferative glomerulonephritis with monoclonal immune deposits (PGNMID) and C3 glomerulopathy associated with monoclonal gammopathy…
- Trial name
- NCT03095118
- Testing
- Daratumumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Fernando Fervenza
Membranous Nephropathy
Adrenocorticotropic Hormone in Membranous Nephropathy
The purpose of this study is to evaluate the effect of adrenocorticotropic hormone (ACTH, Acthar) on the loss of proteins in the urine (proteinuria) in patients with membranous nephropathy.
- Trial name
- NCT03025828
- Testing
- ACTHar
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Anti-Glomerular Basement Membrane Antibody Disease
Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease
This study will evaluate the safety and tolerability of IdeS in patients with severe anti-glomerular basement membrane (anti-GBM) disease receiving standard of care consisting of pulse-methylprednisolone, oral prednisolone and…
- Trial name
- GOOD-IDES-01 (NCT03157037)
- Testing
- Imlifidase
- Where
- 10 sites in Austria, Czechia and 3 more
- Volunteers
- 15 people
- Sponsor
- Mårten Segelmark
IgA Nephropathy
Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
This is an open-label Phase 2a clinical study designed to evaluate the safety and efficacy of AVB-S6-500 in patients with IgA Nephropathy (IgAN). Approximately 24 patients will be enrolled.
- Trial name
- NCT04042623
- Testing
- AVB-S6-500
- Where
- 2 sites in United States, Ukraine
- Volunteers
- 1 people
- Sponsor
- Aravive, Inc.
C3 Glomerulonephritis, Dense Deposit Disease
A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
The primary objective of this study was to determine whether ACH-0144471 (also known as danicopan and ALXN2040) increases blood C3 complement protein (C3) levels in participants with low C3 levels due to either C3G or IC-MPGN.
- Conditions
- C3 Glomerulonephritis, Dense Deposit Disease, C3 Glomerulopathy, Immune Complex Mediated Membranoproliferative Glomerulonephritis
- Trial name
- NCT03124368
- Testing
- Danicopan
- Where
- 3 sites in Australia, Belgium and 1 more
- Volunteers
- 6 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Lupus Nephritis
Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients with active lupus nephritis.
- Trial name
- BLISS-LN (NCT01639339)
- Testing
- Belimumab 10 mg/kg plus standard therapy, Standard therapy
- Where
- 118 sites in United States, Argentina and 19 more
- Volunteers
- 448 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
IgA Nephropathy
Efficacy and Safety of Atacicept in IgA Nephropathy
This main purpose of this study was to evaluate the safety, tolerability, dose response and efficacy of Atacicept in participants with IgA nephropathy and persistent proteinuria.
- Trial name
- NCT02808429
- Testing
- Atacicept 25 mg, Atacicept 75 mg
- Where
- 18 sites in United States, Japan and 1 more
- Volunteers
- 16 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Glomerulonephritis, Membranous
Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis
Study Hypothesis: When mycophenolate mofetil is added to tacrolimus in the treatment of membranous glomerulonephritis it is likely to improve the initial response to treatment and reduce the risk of relapse on stopping therapy.
- Trial name
- MTAC (NCT00843856)
- Testing
- tacrolimus, tacrolimus and mycophenolate mofetil
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Imperial College Healthcare NHS Trust
Proteinuria, Idiopathic Membranous Nephropathy
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
The purpose of this study is to provide nephrologists with additional clinical evidence regarding the efficacy and safety of Acthar in subjects with treatment-resistant idiopathic membranous nephropathy.
- Trial name
- CHART (NCT01386554)
- Testing
- Repository Corticotropin Injection
- Where
- 28 sites in United States, Canada and 3 more
- Volunteers
- 60 people
- Sponsor
- Mallinckrodt
IGA Nephropathy
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy
- Trial name
- NCT02112838
- Testing
- Fostamatinib 150 mg, Fostamatinib 100 mg
- Where
- 20 sites in United States, Austria and 4 more
- Volunteers
- 76 people
- Sponsor
- Rigel Pharmaceuticals
Idiopathic Membranous Nephropathy
MEmbranous Nephropathy Trial Of Rituximab
The primary outcome of this study is to determine whether or not the B cell targeting with Rituximab is non-inferior or more effective than Cyclosporine in inducing long term remission of proteinuria.
- Trial name
- MENTOR (NCT01180036)
- Testing
- Rituximab, Cyclosporine
- Where
- 21 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Mayo Clinic